EVerZom was established with a clear ambition : to improve exosome bioproduction in order to accelerate the development of innovative medical treatments in the long term.

The company secured licenses for patents resulting from exosome research, strengthening its technological foundation.

EVerZom became a recipient of the EIC Accelerator, a major European distinction that reinforced its credibility. In the same year, its bioproduction activity enabled the company to exceed €500K in revenue for the first time, validating the relevance of its business model.

EVerZom signed its first contract with an Asian biotech company, marking a significant step in its international expansion beyond Europe.

The company commissioned its first 
10-liter clinical bioreactor, marking its transition into a more operational phase.

EVerZom closed a €10 million funding round.
This financing will accelerate its clinical programs and support the scaling up of its operations, helping to secure the future therapeutic development to deliver our vision.